

**<insert name of clinic> Announces Use of New Biomarker Testing to Benefit Pulmonary Patients**

*<clinic> will test patients with Biodesix Nodify Lung® Nodule Risk Assessment with the goal of improving care for patients with lung nodules*

CITY, State.— (xyz WIRE)— <insert clinic name, location, descriptor>, today announced that its team of healthcare providers will be using Nodify Lung Nodule Risk Assessment to benefit its pulmonary patients.

Guidelines recommend that clinicians assess the risk of lung cancer in patients with new nodules to inform the next steps for the patient. Today, up to 80% of patients are assigned a low to moderate risk, (or a 5-65% risk of lung cancer), where next medical steps are unclear. Biodesix Nodify Lung test is a first-to-market biomarker test that provides clinicians with an objective assessment of the patient's risk of malignancy. Clinicians use this information to identify lung cancer earlier, prioritize patients for timely procedures, increase malignancy detection rates in biopsy procedures, and help to decrease patient anxiety.

<Insert quote here>

*Sample quote language: "We want to offer our patients the best options for characterizing the risk of malignancy in their lung nodules and that's why we are committed to using Biodesix Nodify Lung testing in our clinical practice," said <insert clinician name, title, etc. > "I believe that the Biodesix blood tests can help to increase a healthcare provider's confidence in clinical decision-making for our patients."*

**About <Clinic | Hospital | Institution>**

<insert boilerplate>

**OPTIONAL:**

**About Biodesix**

Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease, marketed under Nodify Lung® nodule risk assessment and IQLung™ cancer treatment guidance. Biodesix Development Services & Partnerships enable the leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics.

For more information, visit [biodesix.com](https://biodesix.com).

**Clinic Media Contact:**

<insert contact info>

**Biodesix Media Contact:**

Natalie St. Denis

[Natalie.StDenis@biodesix.com](mailto:Natalie.StDenis@biodesix.com)

1-720-925-9285